Evoq Remedies is a pharmaceutical trading company that buys and sells generic drug products and acts as a commission agent for other pharmaceutical entities.
The company lacks any identifiable competitive advantage, as evidenced by razor-thin net margins of 4.1% and a business model based on simple trading. Financial results show a massive disconnect between revenue growth and earnings, while significant related-party loans suggest the entity may function primarily as a financing vehicle for the promoters.
Management has demonstrated poor capital discipline by diverting substantial proceeds from preferential share issues into interest-free loans to related parties. Instead of reinvesting for organic growth, capital is being leaked to promoter-controlled entities while statutory tax and TDS liabilities remain unpaid.
The investment collapsed as the disconnect between soaring revenues and negative earnings growth proved to be a facade for capital siphoning. Regulatory intervention by SEBI and tax authorities likely froze operations following the discovery that preferential issue proceeds were systematically diverted to promoter-controlled entities via interest-free loans. The business, which functioned more as a private piggy bank than a commercial enterprise, eventually buckled under massive unpaid statutory liabilities and the total loss of auditor oversight, leaving minority shareholders with worthless paper in a shell of a company.
RichFakir rates Evoq Remedies Ltd's business quality as poor — 39/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Evoq Remedies Ltd is trading about 32% below our estimate of fair value; we rate its price cheap. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Evoq Remedies Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Evoq Remedies Ltd's fair value is about ₹2 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →